Study Summary
This trial is testing whether doxycycline, a drug commonly used to treat skin conditions and gum disease, can also help prevent heart disease in people who have recently had a heart attack.
Eligible Conditions
- Heart Failure
- Heart Attack
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: 3 months post intervention
Month 3
Composite endpoint of mortality and hospital admission due to re-infarction, heart failure, or stroke
3 months post intervention
Infarct size
Left ventricular ejection fraction (LVEF)
Left ventricular end-diastolic volume index (LVEDVi)
Left ventricular end-systolic volume index (LVESVi)
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Trial Design
2 Treatment Groups
Doxycycline hyclate
1 of 2
Placebo control
1 of 2
Experimental Treatment
Non-Treatment Group
170 Total Participants · 2 Treatment Groups
Primary Treatment: Doxycycline hyclate · Has Placebo Group · Phase 2
Doxycycline hyclate
Drug
Experimental Group · 1 Intervention: Placebo · Intervention Types: DrugPlacebo control
Drug
PlaceboComparator Group · 1 Intervention: Doxycycline Hyclate · Intervention Types: DrugTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Doxycycline
FDA approved
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months post intervention
Who is running the clinical trial?
Royal Alexandra HospitalOTHER
13 Previous Clinical Trials
7,209 Total Patients Enrolled
University of AlbertaLead Sponsor
818 Previous Clinical Trials
376,644 Total Patients Enrolled
22 Trials studying Heart Failure
5,081 Patients Enrolled for Heart Failure
Ian Paterson, MDPrincipal InvestigatorDept. of Medicine, University of Alberta
2 Previous Clinical Trials
733 Total Patients Enrolled
1 Trials studying Heart Failure
518 Patients Enrolled for Heart Failure
Richard Coulden, MDPrincipal InvestigatorDept. of Radiology and Diagnostic Imaging, University of Alberta
Kevin Bainey, MDPrincipal InvestigatorDept. of Medicine, University of Alberta
Richard Schulz, PhDStudy ChairDept. of Pediatrics and Pharmacology, University of Alberta
1 Previous Clinical Trials
380 Total Patients Enrolled
Benjamin Tyrrell, MDStudy DirectorDept. of Medicine, University of Alberta
Richard Thompson, MDPrincipal InvestigatorDept. of Biomedical Engineering, University of Alberta
Peter Hwang, MD, PhDStudy DirectorDept. of Medicine, University of Alberta
Raymond Leung, MDPrincipal InvestigatorCK Hui Heart Centre, Royal Alexandra Hospital, Edmonton, Alberta.
Neil Brass, MDPrincipal InvestigatorDept. of Medicine, University of Alberta
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Symptoms must have started within 12 hours of onset.\n
You are 18 years old or older.
You have a diagnosis of acute ST-elevation myocardial infarction (STEMI).
References
- Schulz, Richard. 2007. “Intracellular Targets of Matrix Metalloproteinase-2 in Cardiac Disease: Rationale and Therapeutic Approaches”. Annual Review of Pharmacology and Toxicology. Annual Reviews. doi:10.1146/annurev.pharmtox.47.120505.105230.
- Cerisano, G., P. Buonamici, R. Valenti, R. Sciagra, S. Raspanti, A. Santini, N. Carrabba, et al.. 2013. “Early Short-term Doxycycline Therapy in Patients with Acute Myocardial Infarction and Left Ventricular Dysfunction to Prevent the Ominous Progression to Adverse Remodelling: The TIPTOP Trial”. European Heart Journal. Oxford University Press (OUP). doi:10.1093/eurheartj/eht420.
- Villarreal, Francisco J., Michael Griffin, Jeffrey Omens, Wolfgang Dillmann, Judy Nguyen, and James Covell. 2003. “Early Short-term Treatment with Doxycycline Modulates Postinfarction Left Ventricular Remodeling”. Circulation. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/01.cir.0000089090.05757.34.
- Schulze, Costas J., Michele M. Castro, Arulmozhi D. Kandasamy, Jonathan Cena, Courtney Bryden, Shoa H. Wang, Arvind Koshal, Ross T. Tsuyuki, Barry A. Finegan, and Richard Schulz. 2013. “Doxycycline Reduces Cardiac Matrix Metalloproteinase-2 Activity but Does Not Ameliorate Myocardial Dysfunction During Reperfusion in Coronary Artery Bypass Patients Undergoing Cardiopulmonary Bypass”. Critical Care Medicine. Ovid Technologies (Wolters Kluwer Health). doi:10.1097/ccm.0b013e318292373c.
- Cheung, Po-Yin, Grzegorz Sawicki, Mieczyslaw Wozniak, Wenjie Wang, Marek W. Radomski, and Richard Schulz. 2000. “Matrix Metalloproteinase-2 Contributes to Ischemia-reperfusion Injury in the Heart”. Circulation. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/01.cir.101.15.1833.
- Cerisano G, Buonamici P, Valenti R, Sciagra R, Raspanti S, Santini A, Carrabba N, Dovellini EV, Romito R, Pupi A, Colonna P, Antoniucci D. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Eur Heart J. 2014 Jan;35(3):184-91. doi: 10.1093/eurheartj/eht420. Epub 2013 Oct 8.
- Villarreal FJ, Griffin M, Omens J, Dillmann W, Nguyen J, Covell J. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation. 2003 Sep 23;108(12):1487-92. doi: 10.1161/01.CIR.0000089090.05757.34. Epub 2003 Sep 2.
- Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol. 2007;47:211-42. doi: 10.1146/annurev.pharmtox.47.120505.105230.
- Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation. 2000 Apr 18;101(15):1833-9. doi: 10.1161/01.cir.101.15.1833.
- 2020. "Doxycycline to Protect Heart Muscle After Heart Attacks". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03508232.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments